Clinical trial NCT05013021: Sprint Interval Training on the Endurance, Strength and Velocity Capacities of Healthy Sedentary Subjects
Official title: Sprint Interval Training (SIT) on the Endurance, Strength and Velocity Capacities of Healthy Sedentary Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sedentary Behavior
Keywords: Sprint Interval Training
VO2max
acute fatigue
chronic fatigue
force-velocity profile
Lead sponsor: Centre Hospitalier Universitaire de Saint Etienne
Sponsor class: OTHER
First posted: 2021-08-19
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Sedentary participants
Primary purpose: OTHER

Brief summary: The present study aims to analyse first, the acute effects generated by a single bout of Sprint Interval Training (SIT) and, secondly, the effects of a long-term intervention on sedentary participants.

Detailed description: The main goal is to determine the optimal dose of high-intensity exercise that enhances the best physiological adaptations.

The cumulative effects of SIT, will be assessed by a series of measures placed throughout the time-course (before, after the 1st , the 2nd and the 3rd block of SIT). Those measures consist of physiological measurements (VO2max), neuromuscular capacities (force-velocity profile) the autonomic nervous system responses (heart rate variability) and blood markers (lactate, Creatine phosphoKinase (CK), cytokinases, µRNA). Acute effects will be measured in the familiarisation sessions (after short (8 sprints) and long (14 sprints) sets) by performing a battery of neuromuscular, perceptual, and autonomic nervous system tests before and after the single session of SIT.

Eligibility criteria: Inclusion Criteria:

* untrained healthy (less than 2 hours of sport per week)
* free from muscular, bone or joint injuries
* free from neurologic disease

Exclusion Criteria:

* taking neuroactive substances that can alter corticospinal excitability
* Heart or respiratory failure.
* Subjects who have taken corticosteroids within 3 months (inhalation, infiltration or history of corticosteroid therapy).
* Pregnant woman
* Subject under guardianship

Primary outcomes:
measure: oxygen uptake (VO2max) - ml/min/kg
timeFrame: At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart
Secondary outcomes:
measure: Maximum power (W)
timeFrame: At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart
measure: Maximum theoretical force (N.m)
timeFrame: At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart
measure: Maximum theoretical speed (m/s)
timeFrame: At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart
measure: Maximum isometric force (N.m)
timeFrame: At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart
measure: heart rate variability (HRV)
timeFrame: At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart
measure: Lactate (mmol/l)
timeFrame: At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart
measure: Cytokines (pg/ml)
timeFrame: At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart
measure: Creatine Kinase (UI/l)
timeFrame: At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart
measure: muscle microRNA
timeFrame: At the end of the 1st, 2nd and 3rd block : Each block = 2 weeks; each block is 1 day apart
Other outcomes:
Locations:
city: Saint-Étienne
country: France
facility: CHU de Saint-Etienne
Study officials:
affiliation: Centre Hospitalier Universitaire de Saint Etienne
name: Leonard FEASSON, MD-PhD
role: PRINCIPAL_INVESTIGATOR
References: